Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 1/20 | 0.59 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10114294 | 0.85 | RXFP1 (0.68) | ABCC8KCNJ11SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12584442 | 0.84 | TRPA1 (0.75) | ABCC8KCNJ11KMT2AMEN1RXFP1 | |
| SCHEMBL18166555 | 0.80 | CYP1A2 (0.70) | ABCC8KCNJ11SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL10114162 | 0.79 | KMT2A (0.70) | SMN1; SMN2KMT2AMEN1RXFP1CYP1A2 | |
| SCHEMBL1064145 | 0.78 | TRPA1 (0.72) | KMT2AMEN1RXFP1CYP1A2TP53 | |
| SCHEMBL20079654 | 0.77 | ALOX15 (0.75) | KMT2ARXFP1CYP1A2TP53ALOX15 | |
| SCHEMBL15375895 | 0.77 | KMT2A (0.74) | SMN1; SMN2KMT2AMEN1RXFP1CYP1A2 | |
| SCHEMBL15394678 | 0.77 | RXFP1 (0.69) | SMN1; SMN2RXFP1CYP1A2TP53ALOX15 | |
| SCHEMBL5464245 | 0.77 | KMT2A (0.67) | SMN1; SMN2KMT2AMEN1RXFP1CYP1A2 | |
| SCHEMBL12584287 | 0.77 | KMT2A (0.67) | SMN1; SMN2KMT2AMEN1RXFP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | ELI LILLY AND COMPANY | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133170-A1 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | TRPA1, TRPV1, TRPV3 | ABCC8 1023/4885KCNJ11 248/4885SMN1; SMN2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.